Bristol Myers Squibb's (BMS) Augtyro (repotrectinib) has been approved by the US Food and Drug Administration (FDA) to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Lung cancer is the leading cause of cancer deaths in the US, with NSCLC representing up to 85% of all lung cancer diagnoses.
More common in individuals with little to no smoking history, the ROS1 gene alteration occurs in only up to 2% of NSCLC patients and is associated with aggressive lung cancer that can often spread to the brain.